Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Basliea

Patient Partnerships: Challenges and Opportunities for Pharma

Durhane Wong-Rieger, President & CEO of the Canadian Organization for Rare Disorders, joins Natalie Yeadon, Co-owner & Managing Director at Impetus Digital, for this live Fireside Chat. Today, we are exploring...

Impetus Digital

- PMLiVE

Audentes’ rare disease gene therapy programme delayed after third patient death

Third patient death caused by gastrointestinal bleeding

- PMLiVE

NICE recommends Astellas’ Xospata for NHS use

Cost-effectiveness watchdog backtracks on previous rejection

The ALS patient journey

Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...

Blue Latitude Health

- PMLiVE

Seattle Genetics makes case for Padcev plus Keytruda in first-line bladder cancer

Hopes to extend the antibody drug conjugate's use into the earlier setting

- PMLiVE

Astellas files new application for expanded use of roxadustat in Japan

Aims for use in anaemia associated with CKD in non-dialysis patients

Life with multiple myeloma – why I’m a lucky man living the dream

Multiple myeloma patient Bob Munro explains what it's like to live with the rare blood cancer and how his diagnosis led him on the journey of a lifetime – cycling...

Blue Latitude Health

- PMLiVE

Astellas bulks up immuno-oncology pipeline with $665m Xyphos deal

Closely follows $3bn acquistion of gene therapy specialist Audentes

- PMLiVE

Seattle, Astellas bag speedy FDA okay for bladder cancer drug

Plans to expand use into earlier bladder cancer treatment

- PMLiVE

Astellas makes gene therapy a core focus with $3bn Audentes buy

Deal includes a late-stage candidate for a rare disease

- PMLiVE

Bedrock are in the Top 3

Bedrock named No. 3 Young Agency by PMLive

Bedrock Healthcare Communications

- PMLiVE

Astellas stays ahead of its FLT3 rivals with EU nod for Xospata

Approval comes after an accelerated review of the drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links